Different HATS of the ING1 gene family

Trends in Cell Biology

Volumn 12, Issue 11, 2002, Pages 532-538

  Feng, Xiaolan ^a   Hara, Yasuo ^b   Riabowol, Karl T ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CELL NUCLEUS ANTIGEN; DNA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; PROTEIN; PROTEIN P21; PROTEIN P53;

ACETYLATION; APOPTOSIS; CELL PROLIFERATION; CHROMATIN; DNA REPAIR; GENE ACTIVITY; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR INTERACTION; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIGENE FAMILY; NUCLEAR PROTEINS; PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036850549     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(02)02391-7     Document Type: Review

References (60)

1. ING1 promotes neoplastic transformation. Nat. Genet. 14:1996;415-420.
2. Stein G.H., et al. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science. 249:1990;666-669.
3. Atadja P.W., et al. Increased activity of p53 in aging human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 92:1995;8348-8352.
4. Vaziri H., et al. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 16:1997;6018-6033.
5. Garkavtsev I., et al. Molecular aspects of the relationship between cancer and aging: tumor suppressor activity during cellular senescence. Exp. Gerontol. 33:1998;81-94.
6. Aasland R., et al. The PHD finger: implications for chromatin mediated transcriptional regulation. Trends Biochem. Sci. 20:1995;56-59.
7. Vieyra D., et al. ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res. 62:2002;4445-4452.
8. Scott M., et al. UV irradiation induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. Nucleic Acids Res. 29:2001;2052-2058.
9. Scott M., et al. DNA damage induces ING1 binding to PCNA. J. Cell Science. 114:2001;3455-3462.
10. ING1 are associated with histone acetyltransferase activities. Mol. Cell. Biol. 20:2000;3807-3816.
11. Choy J.S., et al. Yng2p-dependent NuA4 histone H4 acetylation activity is required for mitotic and meiotic progression. J. Biol. Chem. 276:2001;43653-43662.
12. Nourani A., et al. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex. Mol. Cell Biol. 21:2001;7629-7640.
13. Howe L., et al. Yng1p modulates the activity of Sas3p as a component of the yeast NuA3 Histone acetyltransferase complex. Mol. Cell Biol. 22:2002;5047-5053.
14. Vieyra D., et al. Human ING1 proteins differentially regulate histone acetylation. J. Biol. Chem. 277:2002;29832-29839.
15. Skowyra D., et al. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex. J. Biol. Chem. 276:2001;8734-8739.
16. Kuzmichev A., et al. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol. Cell. Biol. 22:2002;835-848.
17. ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9671-9676.
18. Takahashi M., et al. Identification of the p33ING1-regulated genes which include cyclin B1 and proto-oncogene DEK by using cDNA microarray in a mouse mammary epithelial cell line NMuMG. Cancer Res. 62:2002;2203-2209.
19. Garkavtsev I., et al. Correction and addition to ING1 sequences. Nat. Genet. 23:1999;373.
20. Gunduz M., et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res. 60:2000;3143-3146.
21. Jager D.S., et al. Cancer-testis antigens and the ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologous gene. Cancer Res. 59:1999;6197-6204.
22. ING1. J. Hum. Genet. 45:2000;177-181.
23. Garkavtsev I., et al. Cellular localization and chromosomal mapping of a novel candidate tumour suppressor gene. Cytogenet. Cell Genet. 76:1997;176-178.
24. Shimada Y., et al. Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. Cytogenet. Cell Genet. 83:1998;232-235.
25. Wagner M.J., et al. Expression of novel ING variants is regulated by thyroid hormone in the Xenopus laevis tadpole. J. Biol. Chem. 276:2001;47013-47020.
26. Kawaji H., et al. Exploration of novel motifs derived from mouse cDNA sequences. Genome Res. 12:2002;367-378.
27. Hai T., Hartman M.G. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 273:2001;1-11.
28. Roth S.Y., et al. Histone acetyltransferases. Ann. Rev. Biochem. 70:2001;81-120.
29. Warbrick E. PCNA binding through a conserved motif. BioEssays. 20:1998;195-199.
30. Sager R. Expression genetics in cancer: shifting the focus from DNA to RNA. Proc. Natl. Acad. Sci. U. S. A. 94:1997;952-955.
31. Toyama T., et al. Suppression of ING1 expression in sporadic breast cancer. Oncogene. 18:1999;5187-5193.
32. Ohmori M., et al. Decreased expression of p33ING1 mRNA in lymphoid malignancies. Am. J. Hematol. 62:1999;118-119.
33. Chen L., et al. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res. 61:2001;4345-4349.
34. Merlo A., et al. 5( CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
35. ING3, modulates p53-mediated transcription, cell cycle control and apoptosis. Oncogene (in press)
36. Gunduz M., et al. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene. 21:2002;4462-4470.
37. Helbing C., et al. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res. 57:1997;1255-1258.
38. Shinoura N., et al. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res. 59:1999;5521-5528.
39. ING1 enhances UVB-induced apoptosis in melanoma cells. Exp. Cell Res. (in press)
40. ING1 cooperates with p53 in cell growth control. Nature. 391:1998;295-298.
41. Shimada H., et al. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in human esophageal carcinoma cells. Oncogene. 21:2002;1208-1216.
42. Cheung, K.J., Jr et al. (2001) The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA. Cancer Res. 61, 4974-4977
43. Zheleva D.I., et al. A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics. Biochemistry. 39:2000;7388-7397.
44. ING1 candidate tumor suppressor. Mol. Cell. Biol. 17:1997;2014-2019.
45. Vaziri H., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:2001;149-159.
46. Allfrey V.G. Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc. Canadian Cancer. 6:1966;313-335.
47. Boland D., et al. A panel of Cab antibodies recognize endogenous and ectopically expressed ING1 protein. Hybridoma. 19:2000;161-166.
48. Zeremski M., et al. Structure and regulation of the mouse Ing1 gene: three alternative transcripts encode two PHD finger proteins that have opposite effects upon p53 function. J. Biol. Chem. 274:1999;32172-32181.
49. Cheung K. Jr, Li G. The tumor suppressor ING1: structure and function. Exp. Cell Res. 268:2001;1-6.
50. Hasan S., et al. Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis. Nature. 410:2001;387-391.
51. Barlev N.A., et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 8:2001;1243-1254.
52. Tokunaga E., et al. Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Lett. 152:2000;15-22.
53. Ito K., et al. Expression and sequence analyses of p33(ING1) gene in myeloid leukemia. Am. J. Hematol. 69:2002;141-143.
54. Bromidge T., Lynas C. Relative levels of alternative transcripts of the ING1 gene and lack of mutations of p33/ING1 in haematological malignancies. Leuk. Res. 26:2002;631-635.
55. Krishnamurthy J., et al. Mutational analysis of the candidate tumor suppressor gene ING1 in Indian oral squamous cell carcinoma. Oral Oncol. 37:2001;222-224.
56. Sarela A.I., et al. The candidate tumour suppressor gene, ING1, is retained in colorectal carcinomas. Eur. J. Cancer. 35:1999;1264-1267.
57. Oki E., et al. Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer. Cancer Lett. 147:1999;157-162.
58. Sanchez-Cespedes M., et al. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosomes Cancer. 27:2000;319-322.
59. Campos E.I., et al. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines. Br. J. Dermatol. 146:2002;574-580.
60. Ha S., et al. Mouse ING1 homolog, a protein interacting with A1, enhances cell death and is inhibited by A1 in mammary epithelial cells. Cancer Res. 62:2002;1275-1278.